Pre-IPO Pharma: “Akston Biosciences Announces Publication in Vaccine of Positive Data for a Room Temperature Protein Subunit COVID-19 Vaccine: Shelf stable for at least 6 months, the low-cost SARS-CoV-2 vaccine can be efficiently manufactured anywhere in the world using abundant existing infrastructure”